Docetaxel-prednisolone combination therapy for Japanese patients with hormone-refractory prostate cancer: A single institution experience

Japanese Journal of Clinical Oncology

Volumn 40, Issue 11, 2010, Pages 1092-1098

  Miura, Noriyoshi ^a   Numata, Kosaku ^a   Kusuhara, Yoshito ^a   Shirato, Akitomi ^a   Hashine, Katsuyoshi ^a   Sumiyoshi, Yoshiteru ^a  

^a NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

Author keywords

Chemotherapy; Docetaxel; Hormone refractory; Prostate cancer

Indexed keywords

ANALGESIC AGENT; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN;

ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANEMIA; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER PATIENT; DERMATITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTPATIENT CARE; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PREDNISOLONE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 78049446970     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq100     Document Type: Article

References (17)

1. American Cancer Society (ACS). Cancer facts & figures 2009. http://www.cancer.org/downloads/STT/500809web.pdf (3 September 2009, date last accessed).
2. Center for Cancer Control and Information Services, National Cancer Center, Japan. Vital Statistics of Japan (Ministry of Health, Labour and Welfare). http://ganjoho.jp/professional/statistics.html.
3. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339:1036-42.
4. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14: 1756-64.
5. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
6. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
7. Dagher R, Li N, Abraham S, Rahman A, Sridhara R, Pazdur R. Approval summary: docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clin Cancer Res 2004;10:8147-51.
8. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242-5.
9. Naito S, Tsukamoto T, Koga H, Harabayashi T, Sumiyoshi Y, Hoshi S, et al. Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: multicenter phase II trial in Japan. Jpn J Clin Oncol 2008;38:365-72.
10. Ide H, Kikuchi E, Kono H, Nagata H, Miyajima A, Nakagawa K, et al. Docetaxel in combination with prednisolone for hormone refractory prostate cancer. Jpn J Clin Oncol 2010;40:79-84.
11. Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 2010;46:517-25.
12. Berthold DR, Pond GR, Roessner M, Wit R, Eisenberger M, Tannock IF, et al. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 2008;14:2763-7.
13. Shimazui T, Kawai K, Miyanaga N, Kojima T, Sekido N, Hinotsu S, et al. Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer: a retrospective comparative study with weekly docetaxel alone. Jpn J Clin Oncol 2007;37:603-8.
14. Read WL, Mortimer JE, Picus J. Severe interstitial pneumonitis associated with docetaxel administration. Cancer 2002;94:847-53.
15. Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V, et al. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 2006;79:570-80.
16. Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002;20:3683-90.
17. Ten Tije AJ, Verweij J, Carducci MA, Graveland W, Roqers T, Pronk T, et al. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol 2005;23: 1070-7.